Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:AGLNASDAQ:CERENASDAQ:DOCSNASDAQ:QDEL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAGLAgilon Health$2.12-3.0%$3.03$1.50▼$7.73$873.44M0.144.98 million shs3.12 million shsCERECerevel Therapeutics$44.96$43.67$19.59▼$44.99$8.19B1.41.71 million shsN/ADOCSDoximity$57.47+0.8%$55.53$25.00▼$85.21$10.80B1.322.15 million shs2.64 million shsQDELQuidelOrtho$28.03-1.1%$29.59$23.77▼$49.45$1.90B0.11.09 million shs1.52 million shsA Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAGLAgilon Health0.00%-1.86%-4.30%-53.15%-68.62%CERECerevel Therapeutics0.00%0.00%0.00%0.00%+7.43%DOCSDoximity0.00%+2.79%+12.24%-8.78%+108.54%QDELQuidelOrtho0.00%-3.01%-7.12%-21.99%-21.29%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAGLAgilon Health3.1617 of 5 stars4.14.00.00.03.10.00.6CERECerevel TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ADOCSDoximity2.2981 of 5 stars2.30.00.00.02.24.21.3QDELQuidelOrtho4.5846 of 5 stars3.24.00.03.82.21.72.5Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAGLAgilon Health 2.17Hold$4.79126.27% UpsideCERECerevel Therapeutics 0.00N/AN/AN/ADOCSDoximity 2.59Moderate Buy$62.849.34% UpsideQDELQuidelOrtho 2.43Hold$44.3358.16% UpsideCurrent Analyst Ratings BreakdownLatest DOCS, CERE, AGL, and QDEL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/2/2025DOCSDoximityBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$80.005/27/2025DOCSDoximityJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$63.00 ➝ $60.005/21/2025DOCSDoximityThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetNeutral ➝ Neutral$80.00 ➝ $50.005/20/2025DOCSDoximityRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$87.00 ➝ $65.005/16/2025DOCSDoximityTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetHold ➝ Hold$58.00 ➝ $52.005/16/2025DOCSDoximityMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$65.00 ➝ $60.005/16/2025DOCSDoximityRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$83.00 ➝ $65.005/16/2025DOCSDoximityWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform5/16/2025DOCSDoximityCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetHold ➝ Hold$71.00 ➝ $50.005/16/2025DOCSDoximityNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$82.00 ➝ $67.005/13/2025AGLAgilon HealthWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$6.00 ➝ $5.00(Data available from 6/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAGLAgilon Health$6.06B0.14N/AN/A$1.14 per share1.86CERECerevel TherapeuticsN/AN/AN/AN/A$3.71 per shareN/ADOCSDoximity$570.40M18.93$0.71 per share81.32$5.52 per share10.41QDELQuidelOrtho$2.78B0.68$35.48 per share0.79$44.38 per share0.63Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAGLAgilon Health-$260.15M-$0.59N/AN/AN/A-4.04%-45.47%-12.76%8/5/2025 (Estimated)CERECerevel Therapeutics-$432.84M-$2.73N/AN/AN/AN/A-98.94%-45.07%N/ADOCSDoximity$147.58M$1.1157.4753.714.1036.60%21.75%18.64%N/AQDELQuidelOrtho-$2.05B-$4.97N/A8.73N/A-12.07%4.71%2.21%7/30/2025 (Estimated)Latest DOCS, CERE, AGL, and QDEL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025N/ADOCSDoximity$0.27$0.38+$0.11N/AN/AN/A5/7/2025Q1 2025QDELQuidelOrtho$0.61$0.74+$0.13-$0.19$694.97 million$692.80 million5/6/2025Q1 2025AGLAgilon Health-$0.01$0.03+$0.04$0.03$1.50 billion$1.53 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAGLAgilon HealthN/AN/AN/AN/AN/ACERECerevel TherapeuticsN/AN/AN/AN/AN/ADOCSDoximityN/AN/AN/AN/AN/AQDELQuidelOrthoN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAGLAgilon HealthN/A1.201.20CERECerevel Therapeutics0.6010.2210.22DOCSDoximityN/A8.748.74QDELQuidelOrtho0.701.200.66Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAGLAgilon HealthN/ACERECerevel Therapeutics87.73%DOCSDoximity87.19%QDELQuidelOrtho99.00%Insider OwnershipCompanyInsider OwnershipAGLAgilon Health3.57%CERECerevel Therapeutics5.10%DOCSDoximity37.40%QDELQuidelOrtho0.79%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAGLAgilon Health1,076413.95 million399.17 millionNot OptionableCERECerevel Therapeutics300182.20 million172.90 millionOptionableDOCSDoximity890187.83 million116.87 millionNot OptionableQDELQuidelOrtho6,60067.63 million67.09 millionOptionableDOCS, CERE, AGL, and QDEL HeadlinesRecent News About These CompaniesWhat Makes QuidelOrtho (QDEL) a New Buy StockJune 18, 2025 | zacks.comWhy QuidelOrtho (QDEL) is a Top Growth Stock for the Long-TermJune 18, 2025 | zacks.comShould Value Investors Buy QuidelOrtho (QDEL) Stock?June 18, 2025 | zacks.com3 Reasons to Sell QDEL and 1 Stock to Buy InsteadJune 16, 2025 | msn.comAssenagon Asset Management S.A. Invests $10.92 Million in QuidelOrtho Co. (NASDAQ:QDEL)June 14, 2025 | marketbeat.comQuidelOrtho Co. (NASDAQ:QDEL) Shares Acquired by GAMMA Investing LLCJune 13, 2025 | marketbeat.comQDEL Q1 Earnings Call: Cost Savings and Tariff Mitigation Anchor 2025 OutlookJune 11, 2025 | msn.comPallas Capital Advisors LLC Has $1.29 Million Stock Position in QuidelOrtho Co. (NASDAQ:QDEL)June 11, 2025 | marketbeat.comQuidelOrtho Co. (NASDAQ:QDEL) Stock Position Lowered by Wedge Capital Management L L P NCJune 10, 2025 | marketbeat.comQuidelOrtho Corp (QDEL) Trading 4% Higher on Jun 9June 9, 2025 | gurufocus.comMerit Financial Group LLC Acquires 15,304 Shares of QuidelOrtho Co. (NASDAQ:QDEL)June 9, 2025 | marketbeat.comWealth Enhancement Advisory Services LLC Has $1.52 Million Stock Position in QuidelOrtho Co. (NASDAQ:QDEL)June 7, 2025 | marketbeat.comQuidelOrtho (NASDAQ:QDEL) Raised to Buy at Wall Street ZenJune 7, 2025 | marketbeat.comQuidelOrtho Co. (NASDAQ:QDEL) Stake Increased by California State Teachers Retirement SystemJune 6, 2025 | marketbeat.comBank of America Corp DE Trims Stock Holdings in QuidelOrtho Co. (NASDAQ:QDEL)June 6, 2025 | marketbeat.comQuidelOrtho Declares that its Molecular Diagnostics Approach will be RefocusedJune 4, 2025 | insidermonkey.comUniversal Beteiligungs und Servicegesellschaft mbH Takes $969,000 Position in QuidelOrtho Co. (NASDAQ:QDEL)June 4, 2025 | marketbeat.comQuidelOrtho to discontinue Savanna platform developmentJune 3, 2025 | msn.comQuidelOrtho (QDEL) to Acquire LEX Diagnostics Amid Strategic ShiftJune 3, 2025 | gurufocus.comQuidelOrtho Corp (QDEL) Announces Strategic Shift in Molecular Diagnostics | QDEL stock newsJune 3, 2025 | gurufocus.comQuidelOrtho Announces Strategy to Accelerate Growth in Molecular DiagnosticsJune 3, 2025 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeDOCS, CERE, AGL, and QDEL Company DescriptionsAgilon Health NYSE:AGL$2.12 -0.07 (-2.98%) Closing price 06/20/2025 03:59 PM EasternExtended Trading$2.12 +0.01 (+0.28%) As of 06/20/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.agilon health, inc. provides healthcare services for seniors through primary care physicians in the communities of the United States. It offers a platform that manages the total healthcare needs of the patients by subscription-like per-member per-month. The company was formerly known as Agilon Health Topco, Inc. and changed its name to agilon health, inc. in March 2021. agilon health, inc. was founded in 2016 and is based in Austin, Texas.Cerevel Therapeutics NASDAQ:CERECerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, develops various therapies for neuroscience diseases in the United States. It is developing Emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures or focal epilepsy, as well as in phase 1 trial to treat panic symptoms model. The company's products also comprise Tavapadon, a selective dopamine D1/D5 partial agonist that is in phase 3 clinical trial for the treatment of early- and late-stage Parkinson's disease; CVL-871, a selective dopamine D1/D5 partial agonist, which is in Phase 2a clinical trial to treat dementia-related apathy; and CVL-354, a selective kappa-opioid receptor antagonist to treat major depressive disorder and substance use disorder. It is also involved in the development of an M4 agonist program for the treatment of psychosis and related indications; and PDE4 inhibitor for the treatment of psychiatric, neuroinflammatory, and other disorders. Cerevel Therapeutics Holdings, Inc. was founded in 2018 and is headquartered in Cambridge, Massachusetts.Doximity NASDAQ:DOCS$57.47 +0.43 (+0.76%) Closing price 06/20/2025 03:59 PM EasternExtended Trading$56.62 -0.86 (-1.49%) As of 06/20/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Doximity, Inc. operates a cloud-based digital platform for medical professionals in the United States. The company's platform provides its members with tools built for medical professionals, enabling them to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers. It primarily serves pharmaceutical manufacturers and healthcare systems. The company was formerly known as 3MD Communications, Inc. and changed its name to Doximity, Inc. in June 2010. Doximity, Inc. was incorporated in 2010 and is headquartered in San Francisco, California.QuidelOrtho NASDAQ:QDEL$28.03 -0.30 (-1.06%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$28.02 -0.01 (-0.02%) As of 06/20/2025 05:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides instruments and tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was incorporated in 1979 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New All-Time Highs Coming for Broadcom? Wall Street Says Yes Smith & Wesson Stock Falls on Earnings Miss, Tariff Woes Marvell's New AI Chip Deals Capture Wall Street’s Attention Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer GE Aerospace Turns Engines Into Long-Term Profits 3 Reasons AMD Could Be the Hottest Stock of the Summer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
